Michel Wissing
Overview
Explore the profile of Michel Wissing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wissing M, Brimo F, McKercher G, Scarlata E, Saad F, Carmel M, et al.
Hum Pathol
. 2024 Apr;
146:66-74.
PMID: 38608782
Objectives: To evaluate the International Society of Urological Pathology (ISUP) 5-tier grade grouping (GG) system of prostate cancers as well as previously proposed optimizations. Patients And Methods: The PROCURE biobank...
2.
Tomlin H, Wissing M, Tanikella S, Kaur P, Tabas L
AMIA Annu Symp Proc
. 2024 Jan;
2023:709-717.
PMID: 38222388
Professional medical publications writers (PMWs) cover a wide range of biomedical writing activities that recently includes translation of biomedical publications to plain language summaries (PLS). The consumer health informatics literature...
3.
Kogan L, Matanes E, Wissing M, Mitric C, How J, Amajoud Z, et al.
Gynecol Oncol
. 2020 May;
158(1):84-91.
PMID: 32349874
Objective: To evaluate long-term oncological outcomes and the added value of sentinel lymph node sampling (SLN) compared to pelvic lymph node dissection (LND) in patients with endometrial cancer (EC). Methods:...
4.
Mitric C, Matanes E, Wissing M, Amajoud Z, Abitbol J, Yasmeen A, et al.
J Surg Oncol
. 2020 Apr;
122(2):306-314.
PMID: 32291783
Objective: To evaluate the impact of surgical wait times on outcome of patients with grade 3 endometrial cancer. Methods: All consecutive patients surgically treated for grade 3 endometrial cancer between...
5.
Caffo O, Wissing M, Bianchini D, Bergman A, Thomsen F, Schmid S, et al.
Clin Genitourin Cancer
. 2019 Nov;
18(1):69-76.e4.
PMID: 31767448
Introduction: The sequential use of a number of new agents (NAs) have improved the overall survival (OS) of patients with metastatic castration-resistant prostate cancer whose disease progresses after docetaxel (DOC)...
6.
Wissing M, Mitric C, Amajoud Z, Abitbol J, Yasmeen A, Lopez-Ozuna V, et al.
Gynecol Oncol
. 2019 Jul;
155(1):27-33.
PMID: 31349997
Objective: To assess risk factors for lymph node involvement in patients with endometrial cancer and a body-mass index (BMI) ≥30 kg/m. Materials And Methods: A retrospective analysis was performed of...
7.
Malagon T, Louvanto K, Wissing M, Burchell A, Tellier P, El-Zein M, et al.
Lancet Infect Dis
. 2019 Feb;
19(3):317-326.
PMID: 30745276
Background: Hand-to-genital contact is hypothesised to be a transmission mode of human papillomavirus (HPV) of the Alphapapillomavirus genus. We compared the relative importance of hand-to-genital and genital-to-genital HPV transmission between...
8.
Wissing M, Chevalier S, McKercher G, Laprise C, Aprikian S, OFlaherty A, et al.
World J Urol
. 2018 Aug;
37(5):789-798.
PMID: 30136199
Purpose: We evaluated whether an increased body-mass index (BMI) and decreased physical activity increase the risk of locally advanced or high-risk prostate cancer (PCa) at radical prostatectomy (RP), and treatment...
9.
Wissing M, Brimo F, Chevalier S, Scarlata E, McKercher G, OFlaherty A, et al.
BJU Int
. 2018 Aug;
123(4):624-631.
PMID: 30113732
Objectives: To evaluate the five-tier Gleason grade group (GG) scoring of prostate cancers adopted by the International Society of Urology Pathology (ISUP) in 2014, and to propose modifications to optimize...
10.
Isaacs J, Antony L, Dalrymple S, Brennen W, Gerber S, Hammers H, et al.
Cancer Res
. 2012 Nov;
73(4):1386-99.
PMID: 23149916
Tasquinimod is an orally active antiangiogenic drug that is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer. However, the target of this drug has remained...